IL41767A - Injectable composition for tagging with technetium-99m and its preparation - Google Patents

Injectable composition for tagging with technetium-99m and its preparation

Info

Publication number
IL41767A
IL41767A IL41767A IL4176773A IL41767A IL 41767 A IL41767 A IL 41767A IL 41767 A IL41767 A IL 41767A IL 4176773 A IL4176773 A IL 4176773A IL 41767 A IL41767 A IL 41767A
Authority
IL
Israel
Prior art keywords
macroprotein
set forth
particles
composition
divalent tin
Prior art date
Application number
IL41767A
Other versions
IL41767A0 (en
Original Assignee
Mallinckrodt Chemical Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Chemical Works filed Critical Mallinckrodt Chemical Works
Publication of IL41767A0 publication Critical patent/IL41767A0/en
Publication of IL41767A publication Critical patent/IL41767A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An improved composition suitable for tagging with technetium-99m and use in lung scanning procedures consists essentially of an injectable suspension in buffer solution of particles of a denatured macroprotein having divalent tin bound thereto. The macroprotein has a molecular weight of at least about 20,000. A method for preparing the injectable suspension by treating macroaggregates or microspheres of a denatured macroprotein with a solution containing divalent tin ions is also provided.

Claims (1)

1. A composition suitable for tagging with technetium-r99m and use in lung spanning procedures consisting essentially of an injectable suspension in a buffer solution of particles of denatured macroprotein having divalent tin bound thereto, said macroprotein having a molecular weight of at least about 20,000. 2. A composition as set forth in claim 1 wherein the pH of said buffer solution is approximately the isoelectric pH of said denatured macroprotein. 3. A composition as set forth in claim 1 or 2 wherein said macroprotein comprises particles of macro-aggregated human serum albumin. . A composition as set forth in claim 1, 2 or 3 wherein the size of the particles is substantially between about 5 and about 80 microns. 5. A composition as set, forth in claim wherein the mean size of said particles is between about 15 and about 30 microns. 6. A composition as set forth in any of the preceding claims wherein macroprotein particles are in the form of microspheres. 7. A composition as set forth in any of the preceding claims wherein the buffer solution contains between about 8j¾ and about l6 by weight of an antiagglomer-ating agent selected from the group consisting of propylene glycol, sucrose, glycerin and gelatin. 8. A process for preparing a buffered injectable suspension of particles of denatured macroprptein suitable for tagging with technietium-99m and use in lung scanning procedures comprising the steps of: contacting particles of a denatured macroprotein with a solution containing a water-soluble salt of divalent tin causing divalent tin to be bound to said macroprotein; washing the macroprotein having divalent tin bound thereto with a buffer solution; and thereafter suspending in a buffer solution the macroprotein having divalent tin bound thereto. 9. A process as set forth in claim 8 wherein said macroprotein is human serum albumin. 10. A process as set forth in claim 8 or 9 wherein said solution containing divalent tin ions is a solution of stannous chloride. 11. A process as set forth in claim 10 wherein said solution contains approximately 3 mg. of divalent tin for each 100 mg. of macroprotein, 12. A process as set forth in any of claims 8 to 11 wherein said macroprotein :1s in the form of macro-aggregates, 13. A process as set forth in any of claims 8 to 11 wherein said macroprotein is in the form of macro-spheres.
1. . A process as set forth in any of claims 8 to 13 wherein said macroprotein is prepared by precipitating denatured macroprotein in an acid medium at a pH approximately the isoelectric pH of said protein.
IL41767A 1972-03-20 1973-03-13 Injectable composition for tagging with technetium-99m and its preparation IL41767A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US236159A US3863004A (en) 1972-03-20 1972-03-20 Denatured macroprotein with divalent tin for tagging with technetium-99m and method of preparation

Publications (2)

Publication Number Publication Date
IL41767A0 IL41767A0 (en) 1973-05-31
IL41767A true IL41767A (en) 1976-06-30

Family

ID=22888369

Family Applications (1)

Application Number Title Priority Date Filing Date
IL41767A IL41767A (en) 1972-03-20 1973-03-13 Injectable composition for tagging with technetium-99m and its preparation

Country Status (10)

Country Link
US (1) US3863004A (en)
JP (1) JPS5328971B2 (en)
AU (1) AU472255B2 (en)
BE (1) BE796962A (en)
DE (1) DE2314059A1 (en)
FR (1) FR2182880B1 (en)
GB (1) GB1409176A (en)
IL (1) IL41767A (en)
IT (1) IT989625B (en)
NL (1) NL7303842A (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3968221A (en) * 1972-05-05 1976-07-06 Medi-Physics, Inc. 99M-Technetium labeled tin colloid radiopharmaceuticals
US4024233A (en) * 1972-06-05 1977-05-17 Medi-Physics, Inc. 99M-technetium labeled macroaggregated human serum albumin pharmaceutical
US3987157A (en) * 1974-08-29 1976-10-19 Union Carbide Corporation Technetium 99-m labeled radio-diagnostic agents employing stannous tartrate and method of preparation
US3992513A (en) * 1975-01-07 1976-11-16 Atomic Energy Of Canada Limited Labelled phospholipid material colloidially dispersed and sized to localize at preselected organs
US4057617A (en) * 1975-05-15 1977-11-08 Abramovici J Method of labeling proteins with technetium
GB1535847A (en) * 1976-03-19 1978-12-13 Radiochemical Centre Ltd Technetium-99m labelled tin colloid for body scanning
US4094965A (en) * 1977-04-01 1978-06-13 New England Nuclear Corporation Diagnostic agents containing albumin and method for making same
US4226846A (en) * 1977-04-01 1980-10-07 New England Nuclear Corporation Albumin microaggregates for radioactive scanning of reticuloendothelial systems
US4337240A (en) * 1978-04-20 1982-06-29 New England Nuclear Corporation Denatured albumin complexes for radioscintigraphic imaging and evaluation of reticuloendothelial systems
DE3060377D1 (en) * 1979-08-29 1982-07-01 Nihon Mediphysics Co Ltd 2-oxopropionaldehyde bis(thiosemicarbazone)derivatives and their production and use
JPS5645790U (en) * 1979-09-17 1981-04-24
US4406876A (en) * 1980-10-14 1983-09-27 Research Foundation Of The State Univ. Of New York Sulfur free small-particle production of technetium sulfur colloid
IT1194135B (en) * 1981-01-05 1988-09-14 Novo Industri As COMPOSITIONS OF STABILIZED PLASMINE AND METHOD FOR THEIR PREPARATION
CH652599A5 (en) * 1981-08-28 1985-11-29 Solco Basel Ag Method for producing colloidal physiological degradable, human serum albumin containing products and their use.
JPS61103841A (en) * 1984-10-26 1986-05-22 Nippon Mejifuijitsukusu Kk Stable stannous chloride composition to be fed radioactivity technetium mark
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
DE3728599A1 (en) * 1986-12-10 1988-06-23 Hoechst Ag METHOD FOR PRODUCING AN ORGAN-SPECIFIC SUBSTANCE MARKED WITH TECHNETIUM-99M
US5071965A (en) * 1988-07-19 1991-12-10 Mallinckrodt Medical, Inc. Novel tc-99m complexes
US5096696A (en) * 1990-02-05 1992-03-17 The Research Foundation Of State University Of New York Binding of radiolabeled albumin fragments to fibrin clots
US5137709A (en) * 1991-02-15 1992-08-11 The Dow Chemical Company Layered mixed metal hydroxides for the stabilization of radioactive colloids
US5306482A (en) * 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
WO1993016735A1 (en) * 1992-02-28 1993-09-02 Order Stanley E Use of aggregated proteins to prolong retention time of a therapeutic agent adjacent a targeted site such as a tumor
US6730286B2 (en) 2001-02-28 2004-05-04 Bracco Diagnostics, Inc. Manufacturing process to control particle size
DE10317461A1 (en) * 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt
FI20040240A0 (en) * 2004-02-13 2004-02-13 Nokia Corp Generation of billing information in a communication system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663686A (en) * 1968-04-24 1972-05-16 Minnesota Mining & Mfg Biodegradable radioactive particles
US3663687A (en) * 1968-06-26 1972-05-16 Minnesota Mining & Mfg Biodegradable parenteral microspherules
JPS5637211B2 (en) * 1971-07-20 1981-08-29
US3725295A (en) * 1971-07-20 1973-04-03 Atomic Energy Commission Technetium labeling

Also Published As

Publication number Publication date
AU5337573A (en) 1974-09-19
NL7303842A (en) 1973-09-24
US3863004A (en) 1975-01-28
JPS5328971B2 (en) 1978-08-17
IL41767A0 (en) 1973-05-31
GB1409176A (en) 1975-10-08
JPS4954517A (en) 1974-05-27
AU472255B2 (en) 1976-05-20
IT989625B (en) 1975-06-10
DE2314059A1 (en) 1973-10-04
FR2182880A1 (en) 1973-12-14
FR2182880B1 (en) 1976-04-09
BE796962A (en) 1973-09-19

Similar Documents

Publication Publication Date Title
IL41767A (en) Injectable composition for tagging with technetium-99m and its preparation
Leslie et al. Folate binding by the brush border membrane proteins of small intestinal epithelial cells
KR860000842B1 (en) A method for stabilizing a tumor nectrosis factor
CA1172961A (en) Process for producing substances produced by cells
Shotton et al. Appearance and distribution of surface proteins of the human erythrocyte membrane. An electron microscope and immunochemical labeling study.
EP0483329B1 (en) Novel lyophilized and reconstituted cell compositions
US4289756A (en) Physiological preparation containing loaded cells of expanded volume in suspension, for preferential accumulation in spleen and liver
JPH0740932B2 (en) Cell culture composition and use thereof
JPS6366863B2 (en)
JPS6038111B2 (en) Fixation-dependent cell culture method
US3832338A (en) Orgotein production using a buffer solution containing divalent metal salts
Klotz et al. Interactions of some neutral organic molecules with proteins
US3843444A (en) Membrane separation process
Whiffen et al. Effect of Various Surface Active Agents on Heparin Binding and Clot Formation on Graphite Surfaces.
Rachel The effect of prostaglandin on tumour implantation
AT319252B (en) Process for the preparation of new pyrido [3,2-d] pyrimidines and their acid addition salts
US3687927A (en) Orgotein isolation process employing single ion exchange resin having both acidic and basic groups
JPH0114240B2 (en)
Jamieson et al. Membrane glycoproteins of blood platelets
SE430753B (en) COMBINED HAEMOPHILUS INFLUENZAE-BORDETELLA PERTUSSIS-VACCIN
GB1450598A (en) Insuling preparations
EP0251121A3 (en) Process for inducing the formation of antibodies
JPS59205330A (en) Reagent for producing tin coloid labeled with body scanning technetium-99m
GB1471006A (en) Preparation of albumin
JP2861655B2 (en) Liquid preparation containing human urinary trypsin inhibitor and method for producing the same